December 13, 2024

Joint research on the next generation of sun screens

Joint research on the next generation of sun screens

The German Cancer Research Center (DKFZ) and Beiersdorf are cooperating on the development of innovative sun protection products – and are working together to educate people about effective protection against harmful UV radiation.

Experts predict that climate change and the associated increase in the number of hours of sunshine will lead to a further increase in skin cancer cases. This is particularly to be expected for non-melanoma skin cancer, which is diagnosed around 210,000 times in Germany every year. This term covers squamous cell carcinomas and basal cell carcinomas. Both are considered to be the result of harmful sun exposure. They mainly develop on the skin’s so-called “sun terraces” that are intensely exposed to UV radiation, such as the forehead, nose or ears.

Consistent sun protection can prevent the development of cancer – but what actually happens in the skin when we forget to apply sunscreen? Which molecular processes are triggered by sun exposure in the skin – and how can they possibly be reversed? How does the skin regenerate after sunburn and can it be specifically supported by special substances? And do people with different skin types also need different sun protection that takes into account the respective biological properties of the skin cells?

The DKFZ and Beiersdorf will join forces to research these innovative issues in the future. A newly signed research cooperation agreement has now set the seal on the collaboration, which is initially planned for three years. The aim of the two partners is to develop the next generation of sun screens and care products that support the regeneration of sun-damaged skin in jointly selected research projects. In the best case scenario, this could prevent the development of malignant cells.

Furthermore, the two partners will develop joint campaigns to educate people about the correct use of sunscreen and set up a research clinic for individualized skin cancer prevention at the National Cancer Prevention Center.

“Research into cancer prevention is one of the DKFZ’s core tasks. In the research collaboration with Beiersdorf, we are taking a dual approach: on the one hand, we are focusing on molecular strategies such as the development of agents that prevent healthy cells from developing into skin cancer as a result of UV damage,” says Michael Baumann, Chairman and Scientific Director of the DKFZ. “On the other hand, we want to support people in protecting themselves as best as possible from harmful UV radiation.”

“I am very pleased that our successful collaboration with the DKFZ is continuing. Since 2008, we have been able to decode many secrets of the skin in various projects and contribute to the rapidly growing body of knowledge around skin aging and maintaining skin health,” explains Gitta Neufang, Chief Research & Development Officer at Beiersdorf, adding, “In the more than 140 years of our company history, sun protection has always played an important role. Now, we want to use our expertise and increased education to make an important contribution to counteracting the increase in skin cancer.”

The DKFZ and Beiersdorf are funding the projects for three years with a total of €3.6 million. The two institutions have been closely linked for many years through joint research projects. The cooperation in the field of skin cancer prevention and innovative sun screen is a logical continuation of the successful collaboration.

Our latest News

discover more
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

New AI System Provides Treatment Recommendations for Complex Blood Cancers

New AI System Provides Treatment Recommendations for Complex Blood Cancers

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp